Condition
Neuromyelitis Optica Spectrum Disorders (NMOSD)
Total Trials
6
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 3 (1)
P 4 (1)
Trial Status
Not Yet Recruiting3
Recruiting2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07420296Phase 4RecruitingPrimary
Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
NCT07341828Phase 1Not Yet Recruiting
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
NCT07132398Phase 3Not Yet Recruiting
Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD
NCT06249438Phase 1Recruiting
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
NCT06888622CompletedPrimary
BLAZE-Limiting Approach in NMOSD
NCT06829524Not Yet RecruitingPrimary
HANDLE-a Real World Study on Satralizumab in NMOSD
Showing all 6 trials